Bluebird sends blood disorder drug to FDA for approval; CG Oncology enters collaboration with Roche for Tecentriq
Bluebird bio announced it completed the rolling submission of its BLA to the FDA for betibeglogene autotemcel gene therapy.
The therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
